依那普利对移植后红细胞增多症的控制

Control of post-transplant erythrocytosis by enalapril.

作者信息

Wong K C, Bandler N S, Kerr P G, Atkins R C

机构信息

Department of Nephrology, Monash Medical Centre, Clayton, VIC.

出版信息

Med J Aust. 1994 Nov 7;161(9):544-6. doi: 10.5694/j.1326-5377.1994.tb127600.x.

DOI:10.5694/j.1326-5377.1994.tb127600.x

PMID:7968756

Abstract

OBJECTIVE

To assess the erythropoietin response in patients with erythrocytosis after renal transplantation who were treated with enalapril.

PATIENTS

Fourteen patients with stable renal transplants (creatinine clearance, 74.4 +/- 24.6 mL/min) and a packed cell volume of 51% or more over six months and who had no other cause for their erythrocytosis.

METHODS

Patients were treated with enalapril for six months. Serum erythropoietin levels, creatinine clearance and packed cell volume were measured before and during the study; patients were reviewed each month.

RESULTS

All patients had erythropoietin levels inappropriate for their packed cell volume. After six months' therapy with enalapril their mean erythropoietin concentration of 21.3 +/- 5.0 U/L fell to 7.4 +/- 1.3 U/L (P < 0.02) although the concentration increased in two patients. The mean packed cell volume fell from 52.7% +/- 0.5% to 44.4% +/- 1.0% (P < 0.0001). There was no change in renal function.

CONCLUSION

Low-dose enalapril controls post-transplant erythrocytosis, at least in part, by lowering serum erythropoietin levels.

摘要

目的

评估接受依那普利治疗的肾移植后红细胞增多症患者的促红细胞生成素反应。

患者

14例肾移植稳定患者（肌酐清除率为74.4±24.6 mL/分钟），六个月内血细胞比容达51%或更高，且无其他导致红细胞增多症的病因。

方法

患者接受依那普利治疗六个月。在研究前及研究期间测量血清促红细胞生成素水平、肌酐清除率和血细胞比容；每月对患者进行复查。

结果

所有患者的促红细胞生成素水平与其血细胞比容不相称。接受依那普利治疗六个月后，尽管有两名患者的促红细胞生成素浓度升高，但其平均促红细胞生成素浓度从21.3±5.0 U/L降至7.4±1.3 U/L（P<0.02）。平均血细胞比容从52.7%±0.5%降至44.4%±1.0%（P<0.0001）。肾功能无变化。